Chapter 6 Implications for policy, process and methods

摘要

This final chapter of the main report draws together some of the implications that a more explicit assessment of OIR and AWR might have for policy (e.g. NICE guidance and drug pricing), the process of appraisal (e.g. greater involvement of research commissioners) and methods of appraisal (e.g. should additional information, evidence and analysis be required). Within each of the broad topics discussed below, we try to distinguish between policy issues directly relevant to the NICE remit (at a 'higher level' than the process and methods of technology appraisal); those that might be most relevant to other bodies (e.g. Department of Health, Department for Business, Innovation & Skills) and stakeholders; and specific issues for the process and the methods of technology appraisal. It constitutes a brief discussion of possibilities that NICE and others might choose to take forward. How a consideration of uncertainty and the need for evidence might influence value-based pricing and the impact of patient access schemes on OIR and AWR guidance is also considered. This discussion draws on the feedback provided at both workshops, which included a wide range of relevant stakeholders, including members of NICE and its Advisory Committees (including lay members and other NICE programmes), patient representatives, manufacturers, and research and NHS commissioners, as well as relevant academics. The feedback from both workshops has been summarised and is available online (see www.york.ac.uk/che/research/teehta/workshops/ only-in-research-workshop//).